Sexual Health in the Longevity Era

"Sexual health is the canary in the coal mine. When something goes wrong in the bedroom, it's usually a signal that something has been going wrong in the body for years. Endothelial dysfunction, hormonal decline, metabolic disease — they all show up as sexual symptoms first. If we listen to those signals, we can intervene earlier and more effectively. And for providers, this is a clinical lane that patients are desperate for someone to own."

— Dr. James Hartwell, Men's Health Director, Marron Health

The longevity conversation has exploded in recent years. We talk about healthspan, not just lifespan. We track biomarkers, optimize hormones, dial in sleep, and chase VO2 max numbers. But there's a conspicuous gap in most longevity protocols: sexual health.

It's not because sexual wellness doesn't matter. It's because it's uncomfortable to discuss, historically siloed from "serious" medicine, and — in many clinical settings — simply never asked about. That's changing. A new generation of practitioners and patients are recognizing that sexual function isn't a vanity metric. It's a vital sign. And for providers who take it seriously, it represents one of the highest-demand, highest-retention service lines in modern medicine.

Sexual Health as a Biomarker of Overall Wellness

The idea that sexual function reflects systemic health isn't new, but the evidence base has grown dramatically. Sexual desire, arousal, and performance depend on the coordinated function of the vascular, neurological, hormonal, and psychological systems. When any of these systems falter, sexual health is often the first domino to fall.

"I think of sexual health the way a cardiologist thinks about exercise tolerance," Dr. Hartwell explains. "It's a functional test of multiple organ systems at once. When a patient tells me their libido has dropped or they're having erectile issues, I don't just treat the symptom. I investigate what those symptoms are telling us about their broader health."

Research supports this perspective. Studies have linked sexual dysfunction to increased risk of cardiovascular disease, diabetes, depression, neurological disorders, and all-cause mortality. In men, erectile dysfunction (ED) is one of the strongest early predictors of future cardiovascular events — often preceding a heart attack or stroke by three to five years. In women, declining sexual function correlates with increased inflammatory markers, insulin resistance, and accelerated biological aging.

For clinicians, this reframes the entire conversation. Sexual health screening isn't a nice-to-have. It's a diagnostic gateway — a way to surface cardiometabolic risk, hormonal imbalance, and psychological distress years before conventional markers catch up.

The Cardiovascular Connection

The link between erectile dysfunction and heart disease is one of the most robust associations in men's health research. The mechanism is straightforward: the penile arteries are among the smallest in the body (1-2 mm diameter), while the coronary arteries are larger (3-4 mm). Endothelial dysfunction — the earliest stage of atherosclerosis — affects small vessels first. By the time coronary arteries are compromised enough to cause symptoms, the penile arteries have been struggling for years.

"Erectile dysfunction in a man under 50 with no other risk factors isn't just a sexual health issue — it's a cardiovascular event waiting to happen. Every one of those patients should get a full cardiac workup. If we catch vascular disease at the ED stage, we can intervene years before it becomes a heart attack. This is where the longevity model and sexual medicine converge completely."

— Dr. James Hartwell

The Princeton Consensus Guidelines now formally recommend cardiovascular risk assessment for all men presenting with ED, particularly those under 60 without obvious risk factors. This represents a fundamental shift: ED isn't just a quality-of-life issue. It's a clinical warning sign. And it's a reason your practice should be screening for it routinely — not waiting for patients to bring it up.

Hormonal Assessment for Sexual Dysfunction

Hormones are the biochemical foundation of sexual desire and function. In both men and women, the hormonal landscape shifts significantly with age — and those shifts directly impact sexual wellness. A thorough hormonal workup is the starting point for any serious sexual health evaluation.

The Core Sexual Health Hormone Panel

Dr. Hartwell recommends the following baseline panel for any patient presenting with sexual dysfunction — male or female:

• Total testosterone — The headline number, but often misleading in isolation. Reference ranges are broad (264-916 ng/dL in men), and "normal" doesn't mean optimal. Many symptomatic patients sit in the low-normal range.
• Free testosterone — The unbound, bioavailable fraction that actually reaches tissue. This is the number that correlates most directly with symptoms. Calculate via equilibrium dialysis or direct assay, not the unreliable analog methods.
• SHBG (sex hormone-binding globulin) — The binding protein that determines how much testosterone is bioavailable. SHBG rises with age, thyroid dysfunction, liver disease, and certain medications. Elevated SHBG can render a "normal" total testosterone functionally insufficient.
• Estradiol (sensitive assay) — In men, excess estradiol from aromatase conversion blunts testosterone's effects, contributes to water retention, and can cause gynecomastia. Too little impairs libido and bone health. The sweet spot matters. In women, estradiol decline drives GSM and arousal disorders.
• DHEA-S (dehydroepiandrosterone sulfate) — The most abundant circulating steroid hormone and a precursor to both testosterone and estrogen. DHEA-S declines steadily from the mid-20s onward. Low levels correlate with reduced desire, fatigue, and impaired immune function in both sexes.
• Prolactin — Elevated prolactin suppresses GnRH, reducing testosterone and estrogen production. It's a critical rule-out: hyperprolactinemia (from pituitary adenomas, medications, or hypothyroidism) is a treatable cause of sexual dysfunction that gets missed when providers skip the full panel.

"I've seen men with total testosterone of 600 ng/dL who have no libido because their SHBG is sky-high and their free testosterone is in the gutter. I've seen women with 'normal' estrogen who are completely symptomatic because nobody checked their DHEA-S or free testosterone. You have to look at the full picture — total T, free T, SHBG, estradiol, DHEA-S, and prolactin — to understand what's actually happening. Anything less isn't a workup, it's a guess."

— Dr. James Hartwell

Hormone Optimization in Men

Testosterone is the primary driver of male libido, but the relationship isn't as simple as "more testosterone equals better sex." Free testosterone matters more than total testosterone. SHBG increases with age, binding more testosterone and reducing the amount available for tissue action. Estradiol levels also matter: too much estrogen from aromatase conversion blunts the effects of testosterone, while too little impairs libido and bone health.

Testosterone replacement therapy (TRT) remains the cornerstone intervention for hypogonadal men, but optimizing the full axis — addressing SHBG elevation, managing estradiol conversion, supporting adrenal output via DHEA — produces better outcomes than testosterone monotherapy alone. Clomiphene citrate offers an alternative pathway for younger men or those seeking to preserve fertility, stimulating endogenous production rather than replacing it.

Hormone Optimization in Women

Female sexual health is hormonally complex and, historically, poorly studied. Estrogen, progesterone, and testosterone all play roles. Declining estrogen around perimenopause and menopause leads to vaginal dryness, decreased sensitivity, and reduced blood flow to the genitals. But testosterone — often overlooked in women — is equally important for desire. Women produce testosterone in smaller amounts via the ovaries and adrenal glands, and levels decline by approximately 50% between the ages of 20 and 40.

Low-dose testosterone therapy in women (typically 1-5 mg daily via compounded cream) has shown significant benefits for libido and sexual satisfaction in clinical trials, though it remains off-label in the United States. DHEA supplementation (5-25 mg daily) can support the precursor pool, particularly in women with documented low DHEA-S levels. Local vaginal DHEA (prasterone) is now FDA-approved for dyspareunia related to menopause.

Peptides and PDE5 Inhibitors: The Modern Toolkit

PT-141 (Bremelanotide)

PT-141 is a melanocortin receptor agonist that works through the central nervous system rather than the vascular system. Unlike PDE5 inhibitors (Viagra, Cialis), which increase blood flow mechanically, PT-141 acts on MC3R and MC4R receptors in the hypothalamus to increase sexual desire and arousal. It's FDA-approved for hypoactive sexual desire disorder (HSDD) in premenopausal women under the brand name Vyleesi, and is used off-label in men as well.

"PT-141 fills a gap that PDE5 inhibitors can't. A lot of patients — both men and women — don't have a blood flow problem. They have a desire problem. PT-141 works on the wanting part of the equation, which is fundamentally neurological, not vascular. In my practice, it's become a first-line option for HSDD alongside hormonal optimization."

— Dr. James Hartwell

Common protocols use PT-141 at 1-2 mg subcutaneously, administered 45-60 minutes before sexual activity. Side effects can include nausea (particularly at higher doses), transient flushing, and a temporary increase in blood pressure. Dr. Hartwell recommends starting at 0.5-1 mg to assess tolerance, using it intermittently rather than daily (no more than eight doses per month per FDA labeling), and counseling patients that onset and duration vary individually.

PDE5 Inhibitor Protocols: Beyond Erectile Dysfunction

Sildenafil (Viagra), tadalafil (Cialis), and vardenafil (Levitra) remain the first-line pharmacologic treatments for erectile dysfunction. But their utility extends well beyond as-needed ED management. Structured PDE5 inhibitor protocols are becoming a cornerstone of longevity-oriented men's health practices.

Daily Low-Dose Tadalafil Protocol

Daily tadalafil at 2.5-5 mg has emerged as a multi-benefit intervention:

• Erectile function — Continuous PDE5 inhibition provides reliable baseline erectile support without timing requirements
• Lower urinary tract symptoms — FDA-approved for BPH; reduces frequency, urgency, and nocturia
• Endothelial function — Ongoing research suggests cardiovascular protective effects via nitric oxide pathway enhancement
• Exercise performance — Improved blood flow and reduced pulmonary artery pressure, particularly at altitude
• Penile rehabilitation — Maintains erectile tissue health in men undergoing hormone therapy, recovering from prostate procedures, or experiencing age-related smooth muscle decline

"Daily low-dose tadalafil is becoming one of those drugs that practitioners in the longevity space use almost like a nutraceutical," Dr. Hartwell observes. "The vascular benefits go well beyond erections. It's a vasodilator, an endothelial protectant, and a smooth muscle relaxant all in one. For men over 40 with any cardiovascular risk, the risk-benefit ratio is compelling."

On-Demand Protocols and Combination Approaches

For patients who prefer as-needed treatment, sildenafil (25-100 mg, 30-60 minutes before activity) offers rapid onset with a shorter duration. Vardenafil provides similar pharmacokinetics. Some clinicians combine daily low-dose tadalafil with on-demand sildenafil for patients with more severe ED, though this requires careful blood pressure monitoring.

The combination of PDE5 inhibitors (vascular) with PT-141 (central/desire) addresses both the mechanical and motivational components of sexual function — a "dual pathway" approach that is gaining traction in integrative sexual medicine.

Female Sexual Dysfunction: The Underdiagnosed Epidemic

Female sexual dysfunction (FSD) affects an estimated 40% of women at some point in their lives, yet it remains dramatically underdiagnosed and undertreated. The reasons are both cultural and clinical: many women don't raise the issue with their doctors, and many doctors don't ask.

"We have a massive diagnostic gap," Dr. Hartwell says. "A man walks in with erectile dysfunction, and we have a clear clinical pathway — labs, vascular assessment, treatment options. A woman walks in with low desire or painful intercourse, and too often she's told it's stress, it's normal, or it's in her head. That's not acceptable medicine. And frankly, it's a massive clinical gap that forward-thinking practices should be rushing to fill."

Key Areas of Female Sexual Health

• Hypoactive sexual desire disorder (HSDD) — Persistent lack of desire that causes distress; treatable with hormonal optimization (testosterone, DHEA), PT-141, and flibanserin (Addyi)
• Genitourinary syndrome of menopause (GSM) — Vaginal dryness, irritation, and painful intercourse caused by estrogen decline; highly responsive to local estrogen therapy and vaginal DHEA (prasterone)
• Arousal disorders — Difficulty with physical arousal despite desire; can reflect vascular, neurological, or hormonal causes. Emerging evidence supports off-label use of low-dose sildenafil in select patients.
• Orgasmic dysfunction — Difficulty reaching orgasm; often related to medication side effects (especially SSRIs), pelvic floor dysfunction, or hormonal factors
• Pain disorders (dyspareunia, vaginismus) — Require specialized evaluation including pelvic floor assessment, vulvar dermatology, and psychological screening

The longevity era demands that female sexual health receive the same rigorous, evidence-based attention that we give to cardiovascular risk, metabolic health, and cognitive function. Sexual wellness is not a luxury — it's a component of healthspan. And for providers, the unmet demand is staggering: women are actively seeking clinicians who will take these concerns seriously.

Lifestyle Foundations: Sleep, Stress, and the Pelvic Floor

Before prescriptions and peptides, lifestyle factors exert enormous influence over sexual function — often more than patients realize. For providers, this is also where high-value coaching and follow-up visits live.

Sleep and Libido

Sleep deprivation crushes sexual desire through multiple pathways. It suppresses testosterone production (in both sexes), elevates cortisol, reduces dopamine sensitivity, and simply leaves people too exhausted to be interested. Research from the University of Chicago showed that men sleeping five hours per night for one week had testosterone levels equivalent to someone 10-15 years older.

Stress: The Desire Killer

Chronic stress is arguably the single most common cause of reduced sexual desire in otherwise healthy adults. The mechanism is both hormonal (elevated cortisol suppresses gonadotropins) and psychological (anxious, overwhelmed people don't feel safe enough to be sexual). Stress management isn't just a nice-to-have — it's a sexual health intervention.

Pelvic Floor Health: The Most Underutilized Intervention

The pelvic floor muscles play a critical role in sexual function for both men and women. In men, pelvic floor strength contributes to erectile rigidity and ejaculatory control. In women, pelvic floor tone affects sensation, arousal, and orgasm intensity. Pelvic floor dysfunction — whether hypertonic (too tight) or hypotonic (too weak) — can significantly impair sexual function.

Hypertonic pelvic floor is particularly underrecognized. It's often the culprit behind pain during intercourse, chronic pelvic pain, and even erectile dysfunction that doesn't respond to PDE5 inhibitors. Patients with hypertonic pelvic floor need down-training and manual therapy, not Kegels — a critical distinction that requires proper assessment.

"Pelvic floor therapy is one of the most underutilized interventions in sexual medicine. I've had patients who spent years trying different medications when what they actually needed was eight sessions with a pelvic floor physical therapist. The results can be remarkable. If your practice doesn't have a referral relationship with a pelvic floor PT, build one. It's essential."

— Dr. James Hartwell

When to Seek Clinical Evaluation

Sexual health concerns exist on a spectrum. Occasional changes in desire, arousal, or performance are normal and usually related to stress, sleep, or relationship dynamics. But persistent changes deserve clinical attention — both for quality of life and because they may signal underlying health issues.

Consider evaluation if you experience:

• Erectile dysfunction lasting more than three months (men)
• Persistent low desire that causes personal distress (men and women)
• Pain during intercourse that doesn't resolve with lubrication (women)
• Significant changes in sexual function after starting a new medication
• Sexual dysfunction accompanied by other symptoms — fatigue, weight changes, mood shifts, brain fog
• Any sudden onset of erectile dysfunction (may indicate vascular or neurological emergency)
• Difficulty with arousal or orgasm that represents a change from your baseline

"The most important thing is to not normalize it," Dr. Hartwell emphasizes. "If your sexual health has changed and it bothers you, that's enough reason to get evaluated. You don't need to meet some clinical threshold to deserve answers. And I'd add — find a provider who actually specializes in this. Sexual health is a clinical discipline, not an afterthought."

Aging and Sexual Wellness: The New Paradigm

The old model said sexual decline was an inevitable part of aging — something to accept quietly. The longevity model says otherwise. With the right combination of hormonal optimization, lifestyle interventions, targeted therapies, and clinical monitoring, sexual wellness can be maintained and even improved well into the later decades of life.

Sexual health isn't separate from health. It is health. And in the longevity era, it deserves a seat at the table — in every patient conversation, every intake form, and every practice model.

Building Sexual Health Into Your Practice

For providers reading this, the clinical case for sexual health is clear. But there's also a compelling business case. Sexual health is one of the fastest-growing verticals in outpatient medicine, driven by patient demand, favorable reimbursement dynamics, and the shift toward longevity-oriented care models.

The Business Case

• Massive unmet demand — An estimated 30 million men in the US have ED; 40% of women experience FSD. Most are undertreated or untreated entirely. Patients are actively searching for providers who will address these concerns.
• High patient retention — Sexual health patients require ongoing management: hormone monitoring, medication titration, follow-up labs. This is inherently longitudinal care with strong retention rates.
• Cash-pay friendly — Many sexual health services (hormone optimization, peptide therapy, PDE5 prescriptions via membership) map naturally to cash-pay or hybrid models, reducing insurance dependency.
• Natural cross-sell — Sexual health patients often need metabolic optimization, mental health support, and preventive cardiology. One service line feeds others.
• Telehealth compatible — Follow-up consultations, lab reviews, and medication management are well-suited to virtual visits, expanding your geographic reach.

Getting Started: The Minimum Viable Sexual Health Program

You don't need to become a fellowship-trained sexual medicine specialist to offer meaningful sexual health services. Here's a practical framework for men's and women's health practices:

1. Screen routinely — Add validated sexual health questionnaires (IIEF for men, FSFI for women) to your intake process. Normalize the conversation by making it part of every wellness visit.
2. Order the right labs — Use the comprehensive panel described above: total testosterone, free testosterone, SHBG, estradiol (sensitive assay), DHEA-S, and prolactin. Add thyroid panel, metabolic markers, and CBC as appropriate.
3. Build your formulary — PDE5 inhibitors (tadalafil, sildenafil), PT-141, testosterone (multiple delivery forms), DHEA, and local estrogen/prasterone. Partner with a compounding pharmacy for custom formulations.
4. Establish referral relationships — Pelvic floor physical therapy, urology, gynecology, and mental health. You don't need to treat everything — you need to coordinate everything.
5. Create follow-up protocols — Sexual health is not a one-visit fix. Build structured follow-up cadences: labs at 6-8 weeks post-initiation, then quarterly, with symptom reassessment at each visit.
6. Invest in technology — Secure messaging, discreet intake forms, telehealth capability, and lab integration are non-negotiable for sexual health. Patients need to feel that their information is handled with care.

"The practitioners who take sexual health seriously — who ask about it, measure it, and treat it with the same rigor as metabolic or cardiovascular health — will be the ones delivering truly comprehensive longevity care. And they'll build practices that patients never want to leave, because they're finally getting the care they've been searching for."

— Dr. James Hartwell